The use of a noninvasive colorectal cancer screening test called a multi-target stool DNA test (mt-sDNA) detected the disease in patients who had previously avoided more invasive screening procedures.
Results of the I-SPY 2 TRIAL found that the neoadjuvant combination of T-DM1 plus pertuzumab resulted in a greater benefit to HER2-positive breast cancer patients compared with paclitaxel plus trastuzumab.
Researchers have identified two species of bacteria linked with periodontal disease in healthy individuals that are associated with a risk of developing pancreatic cancer.
Immunotherapy treatment with nivolumab significantly improved survival among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Prostate cancer patients who kept up a moderate to high level of physical activity had better survival prognoses compared with their more sedentary counterparts.
Results of a trial involving a CD4-based immunotherapy has shown activity in patients with metastatic solid tumors, according to phase I data presented at the AACR Annual Meeting.
More than one-third of patients with advanced melanoma were still alive 5 years after starting treatment with the anti-PD-1 immunotherapy nivolumab, according to long-term phase I data.
New data indicates that entrectinib has clinical activity in patients with a variety of cancers with gene alterations in NTRK1/2/3, ROS1, or ALK who had never been treated with targeted agents.